
IO Biotech (NASDAQ:IOBT) dosed first patient in its phase 3 clinical trial of lead drug candidate, IO102-IO103, in combination with Merck's KEYTRUDA® (pembrolizumab) in patients with previously untreated, unresectable or metastatic (advanced) melanoma.
The Phase 3 IOB-013 / KN-D18 clinical trial will evaluate IO102-IO103 in combination with Merck's anti-PD-1therapy for patients with metastatic (advanced) melanoma.